Cysteine requirements for preterm infants

Submission date	Recruitment status	Prospectively registered
20/12/2005	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
20/12/2005	Completed	Results
Last Edited	Condition category	Individual participant data
04/11/2008	Neonatal Diseases	Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Ms M A Riedijk

Contact details

Erasmus Medical Centre
Sophia Children's Hospital
Department of Neonatology, Room SP3433
P.O. Box 2060
Rotterdam
Netherlands
3000 CB
+31 (0)10 463 6363
m.riedijk@erasmus.nl

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

NTR245

Study information

Scientific Title

To determine the requirement of cysteine in preterm infants with different gestational ages and post-natal age

Study objectives

- 1. Cysteine is an essential amino acid for newborn preterm infants
- 2. Cysteine requirements change rapidly with postnatal age
- 3. The change in cysteine requirement with age is based upon cystathionase activity
- 4. Intestinal cystathionase activity is of major importance for the conversion of methionine to cysteine

Ethics approval required

Old ethics approval format

Ethics approval(s)

Received from the local medical ethics committee

Study design

Multicentre, randomised, single blind, active controlled, crossover trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Premature infants, glutathione (GSH) deficiency

Interventions

Infants receive a test diet with graded amounts of cystine for 32 hours.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Cystine

Primary outcome measure

- 1. Fractional oxidation of 13C-phenylalanine
- 2. Whole body flux of 13C-phenylalanine

Secondary outcome measures

No secondary outcome measures

Overall study start date

01/11/2004

Completion date

01/06/2006

Eligibility

Key inclusion criteria

- 1. Infants born with a gestational age of 26 29 weeks will be studied at a post-conceptional age of 30 32 weeks and at a post-conceptional age of 35 37 weeks
- 2. Infants born at a gestational age of 32 34 weeks will also be studied at a post-conceptional age of 35 37 weeks

Participant type(s)

Patient

Age group

Neonate

Sex

Both

Target number of participants

80

Key exclusion criteria

- 1. Congenital metabolic disease
- 2. Congenital anomalies
- 3. Gastrointestinal diseases

Date of first enrolment

01/11/2004

Date of final enrolment

01/06/2006

Locations

Countries of recruitment

Netherlands

Study participating centre Erasmus Medical Centre

Rotterdam Netherlands 3000 CB

Sponsor information

Organisation

Sophia Foundation For Scientific Research (SSWO) (Netherlands)

Sponsor details

P.O. Box 2060 Rotterdam Netherlands 3000 CB +31 (0)10 463 6079 info@vriendensophia.nl

Sponsor type

Research organisation

Website

http://www.vriendensophia.nl/?/sophia_home/welkom

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

Sophia Children's Hospital Fund (The Netherlands)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summaryNot provided at time of registration